BiotechTube

Irinotecan

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unspecified Adult Solid Tumor

Conditions

Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Neoplasms, Solid Tumor

Trial Timeline

— → —

NCT ID
NCT00037804

About Irinotecan

Irinotecan is a phase 1 stage product being developed by Pfizer for Unspecified Adult Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00037804. Target conditions include Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT00037804Phase 1Completed
NCT00136955Phase 2Completed
NCT00072852Phase 2Completed

Competing Products

20 competing products in Unspecified Adult Solid Tumor

See all competitors
ProductCompanyStageHype Score
DJ-927 + capecitabineDaiichi SankyoPhase 1
33
E7389 + E7389 + E7389EisaiPhase 1
33
bevacizumab + enzastaurin hydrochlorideEli LillyPhase 1
33
SHR-1916Jiangsu Hengrui MedicinePhase 1
33
PembrolizumabMerckPhase 2
52
PI3K inhibitor BKM120 + docetaxelNovartisPhase 1
33
bevacizumab + cyclophosphamide + imatinibNovartisPhase 1
33
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)NovartisPhase 1
33
warfarinNovartisPhase 1
33
RLY-1971RochePhase 1
33
Domvanalimab + ZimberelimabGilead SciencesPhase 1
32
BEZ235 + MEK162PfizerPhase 1
32
Utomilumab + ISA101bPfizerPhase 2
51
Ixabepilone + SunitinibPfizerPhase 1
32
ixabepilone + lapatinib ditosylateBristol Myers SquibbPhase 1
32
carboplatin + irinotecan hydrochlorideBristol Myers SquibbPhase 1
32
intoplicineSanofiPhase 1
32
apomineSanofiPhase 1
32
apomineSanofiPhase 1
32
SorafenibBayerPhase 2
49

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84